Login to Your Account

TopoTarget Extravasation Drug Approved In EU; Not Yet In U.S.

By Jennifer Boggs

Friday, August 4, 2006
Danish company TopoTarget A/S reported European approval and a U.S. approvable letter for its first product, a drug designed to protect a cancer patient's tissue from the effects of anthracyclines upon accidental exposure during the administration of chemotherapy. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription